1. Election of chairman of the meeting
The board proposed Rolf Lavigné Ussing as chairman of the meeting.  The proposal was accepted.

The chairman concluded that the Annual General Meeting (AGM) was announced in accordance with the Articles of Association section 5.1.  Notice of the AGM was sent in due time the 30th of January 2023.

The notice was in accordance with section 5.2.

The chairman ascertained that the number of voting shares was 8.122.174.  The total number of shares of the company amount to 12.322.635.

2. Presentation of the annual report with auditors’ report for adoption
The AGM resolved in accordance with the Board of Directors’ proposal, to approve the annual report presented during the AGM, with all votes represented at the AGM.

3. Resolution concerning the appropriation of profits or losses as recorded in the adopted annual report
The AGM resolved, in accordance with the Board of Directors’ proposal, that the result for the period 1 October 2020 – 30 September 2021 (DKK -10.802.971 ) is carried forward to the following year, with all votes represented at the AGM..

4. Election of members to the board of directors
The AGM resolved, in accordance with the Board of Directors’ proposal, that the Board members, were re-elected, except Stein Lokstad who resign from the board.  The decision was supported by all votes represented at the AGM.

5. Election of auditor
The AGM resolved, in accordance with the board of directors’ proposal, that the existing auditor Christensen Kjærulff Statsautoriseret Revisionsaktieselskab was re-elected. The decision was supported by all votes represented at the AGM.

6. Authorization for the board of directors to issue incentive warrants up to 5% of the current share capital
The AGM resolved, in accordance with the board of directors’ proposal, and authorises the board of directors to issue warrants to the Company’s board of directors, executive management and ordinary employees. The authorization shall be valid for a period of 5 years from the date of the extraordinary general meeting. The board of directors shall be authorized to issue warrants corresponding to nominally DKK 40,040 shares (which is equal to approx. 5% of the Company’s current share capital). The autorisation will be adopted in the Company’s articles of association.

The decision was supported by all votes represented at the AGM.

7. Change of the financial year to the calendar year
The AGM resolved, in accordance with the board of directors’ proposal, that the Company’s financial year (October 1 – September 30) is changed to the calender year. The conversion period will be from 1 October 2023 to 31 December 2023. The Company’s articles of association will be amended accordingly.

The decision was supported by all votes represented at the AGM.

8. Any other business
The Chairman ascertained that no other business was to be dicussed.

This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on 14-02-2023 17:52 CET.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments for autoimmune and stress-related disorders under the trademark CANNASEN® or own label options.

The company is listed on Spotlight Stock Market in Denmark (symbol: "CSMED"). more information, visit cs-medica.com, and LinkedIn.